Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024
CARMIEL, Israel, May 3, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March 31, 2024 and provide a business and clinical update on May 10, 2024.
- Management will host a conference call with investors to discuss the financial results and provide an update on recent corporate and regulatory developments.
- The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.
- Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software.
- A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.